Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer
Loading...
Date
2000
Authors
Dannull, Jens
Diener, Pierre-André
Prikler, Ladislav
Fürstenberger, Gregor
Cerny, Thomas
Schmid, Ulrico
Ackermann, Daniel K.
Editors
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
URI (citable link)
International patent number
Link to the license
EU project number
Project
Open Access publication
Collections
Title in another language
Publication type
Journal article
Publication status
Published in
Cancer Research ; 60 (2000), 19. - pp. 5522-5528. - ISSN 0008-5472. - eISSN 1538-7445
Abstract
Immunotherapy of prostate cancer (CaP) may be a promising novel treatment option for the management of advanced CaP. However, the lack of suitable tumor antigens remains a major obstacle for the rational design of vaccines. To characterize potential CaP antigens, we determined the mRNA expression of the prostate-specific genes C1, C2, C5, PAGE-1, and prostate stem cell antigen (PSCA) in hormone-refractory CaP, benign prostatic hyperplasia, CaP cell lines, and CaP specimens. Among these gene products, only expression of PSCA appears to be retained in the majority of advanced CaP samples, as shown by reverse transcription-PCR analyses. Peptide fragments of PSCA presented in the context of major histocompatibility molecules could serve as recognition targets for CD8 T cells, provided these lymphocytes were not clonally deleted or peripherally tolerized. Our goal was to determine whether the human T-cell repertoire could recognize PSCA-derived peptide epitopes in the context of a common class I allele, HLA-A0201. Of nine peptides that, according to HLA-A0201 binding motifs, were candidate ligands of A0201 class I molecules, three peptides were able to stabilize HLA-A0201 molecules on the cell surface. One of the latter peptides, encompassing amino acid residues 14-22, was capable of generating a PSCA-specific T-cell response in a human lymphocyte culture from a patient with metastatic CaP. PSCA-specific CTLs recognized peptide-pulsed targets as well as three prostate carcinoma lines in cytotoxicity assays, indicating that this peptide could be endogenously processed. In conclusion, our findings establish PSCA as a potential target for antigen-specific, T cell-based immunotherapy of prostate carcinoma.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690
DANNULL, Jens, Pierre-André DIENER, Ladislav PRIKLER, Gregor FÜRSTENBERGER, Thomas CERNY, Ulrico SCHMID, Daniel K. ACKERMANN, Marcus GRÖTTRUP, 2000. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. In: Cancer Research. 60(19), pp. 5522-5528. ISSN 0008-5472. eISSN 1538-7445BibTex
@article{Dannull2000Prost-22163, year={2000}, title={Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer}, url={http://cancerres.aacrjournals.org/content/60/19/5522}, number={19}, volume={60}, issn={0008-5472}, journal={Cancer Research}, pages={5522--5528}, author={Dannull, Jens and Diener, Pierre-André and Prikler, Ladislav and Fürstenberger, Gregor and Cerny, Thomas and Schmid, Ulrico and Ackermann, Daniel K. and Gröttrup, Marcus} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/22163"> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>Prikler, Ladislav</dc:creator> <dc:creator>Cerny, Thomas</dc:creator> <dc:creator>Schmid, Ulrico</dc:creator> <dc:contributor>Dannull, Jens</dc:contributor> <dc:rights>terms-of-use</dc:rights> <dc:contributor>Schmid, Ulrico</dc:contributor> <dc:creator>Dannull, Jens</dc:creator> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/22163/2/Dannull_221637.pdf"/> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/22163"/> <dc:creator>Diener, Pierre-André</dc:creator> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-27T08:47:39Z</dc:date> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:issued>2000</dcterms:issued> <dc:language>eng</dc:language> <dc:contributor>Prikler, Ladislav</dc:contributor> <dc:contributor>Cerny, Thomas</dc:contributor> <dc:contributor>Gröttrup, Marcus</dc:contributor> <dc:creator>Fürstenberger, Gregor</dc:creator> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <dc:contributor>Diener, Pierre-André</dc:contributor> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-27T08:47:39Z</dcterms:available> <dc:contributor>Ackermann, Daniel K.</dc:contributor> <dc:contributor>Fürstenberger, Gregor</dc:contributor> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/22163/2/Dannull_221637.pdf"/> <dcterms:title>Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer</dcterms:title> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dcterms:abstract xml:lang="eng">Immunotherapy of prostate cancer (CaP) may be a promising novel treatment option for the management of advanced CaP. However, the lack of suitable tumor antigens remains a major obstacle for the rational design of vaccines. To characterize potential CaP antigens, we determined the mRNA expression of the prostate-specific genes C1, C2, C5, PAGE-1, and prostate stem cell antigen (PSCA) in hormone-refractory CaP, benign prostatic hyperplasia, CaP cell lines, and CaP specimens. Among these gene products, only expression of PSCA appears to be retained in the majority of advanced CaP samples, as shown by reverse transcription-PCR analyses. Peptide fragments of PSCA presented in the context of major histocompatibility molecules could serve as recognition targets for CD8 T cells, provided these lymphocytes were not clonally deleted or peripherally tolerized. Our goal was to determine whether the human T-cell repertoire could recognize PSCA-derived peptide epitopes in the context of a common class I allele, HLA-A0201. Of nine peptides that, according to HLA-A0201 binding motifs, were candidate ligands of A0201 class I molecules, three peptides were able to stabilize HLA-A0201 molecules on the cell surface. One of the latter peptides, encompassing amino acid residues 14-22, was capable of generating a PSCA-specific T-cell response in a human lymphocyte culture from a patient with metastatic CaP. PSCA-specific CTLs recognized peptide-pulsed targets as well as three prostate carcinoma lines in cytotoxicity assays, indicating that this peptide could be endogenously processed. In conclusion, our findings establish PSCA as a potential target for antigen-specific, T cell-based immunotherapy of prostate carcinoma.</dcterms:abstract> <dc:creator>Ackermann, Daniel K.</dc:creator> <dc:creator>Gröttrup, Marcus</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:bibliographicCitation>Cancer Research ; 60 (2000), 19. - S. 5522-5528</dcterms:bibliographicCitation> </rdf:Description> </rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
URL of original publication
Test date of URL
2017-12-21
Examination date of dissertation
Method of financing
Comment on publication
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
No